Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity Conference being held today in Stockholm, Sweden. BioEquity is the top European event for life science investors showcasing companies on the forefront of innovation. Presenting companies are hand-chosen based on rigorous selection criteria, including investor validation, upcoming milestones, un-partnered assets and innovative science.
Auxogyn’s flagship commercially launched product, the Early Embryo Viability Assessment™ (Eeva™) Test, is designed to improve embryo selection by providing clinicians with objective information to more confidently select embryo(s) for transfer. The Eeva test is enabled by time-lapse imaging analysis and utilizes intelligent computer vision software to automatically analyze key scientifically and clinically validated cell-division parameters. Eeva is clinically proven tohelp IVF teams determine which embryos have the highest developmental potential to grow to the blastocyst stage, a critical milestone in embryo development which ultimately can help IVF teams achieve better outcomes.
“We’re honored to be selected as a presenting company,” said Lissa Goldenstein, CEO and President of Auxogyn. “Since our launch last fall, the Eeva test has been helping IVF teams improve embryo selection which ultimately can help couples achieve their dreams of building a family. It is exciting to be here today to share our progress with others on the cutting edge of innovation.”
IVF clinics in the UK and Ireland were the first in the world to offer the Eevatest and the company has received significantly positive feedback from the IVF clinics which have since adopted the innovative technology. As a result, the company is planning for rapid expansion beyond the UK and Ireland markets into other parts of the globe.
The Auxogyncorporate presentation will take place at 5.30pm CET on Wednesday May 22 at the BioEquity Conference.
